Cingulate Inc.CINGEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Cingulate Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system disorders, including attention-deficit/hyperactivity disorder, anxiety and depression. It primarily operates in the U.S. market, focusing on advancing its proprietary precision drug delivery platform to improve patient outcomes across psychiatric and neurological care segments.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| s. | 4.51% | 98.2K | ▼ -1.17pp | 2024-08-30 |
| Nos. of above persons | 3.10% | 98.9K | ▼ -6.80pp | 2024-11-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-09 | Callahan Jennifer L. | EVP and CFO | Grant | 15.3K | $0.00 | $0 |
| 2026-03-09 | Patel Nilay Dahyabhai | EVP, CLO and CCO | Grant | 5.5K | $0.00 | $0 |
| 2026-03-09 | Matthew Brams | EVP and Chief Medical Officer | Grant | 4.5K | $0.00 | $0 |
| 2026-03-09 | Silva Raul R. | EVP and CSO | Grant | 4.5K | $0.00 | $0 |
| 2026-03-09 | Schaffer Shane J. | Chief Executive Officer | Grant | 6.9K | $0.00 | $0 |
1–5 of 5